Results 81 to 90 of about 186,128 (186)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration [PDF]

, 2015
Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard.
Alfredo García-Layana, Enrique Cervera, Felix Armadá, Francisco Cabrera-López, Francisco Gómez-Ulla, Javier Araiz, Jordi Monés, José García-Arumí, José Manuel García-Campos, José María Ruiz-Moreno, Luis Arias, Marta S. Figueroa, María Isabel López-Gálvez, Roberto Gallego-Pinazo   +13 more
core   +3 more sources

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

Clinical Ophthalmology, 2018
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of
Taipale C, Laine I, Tuuminen R
doaj  

The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis [PDF]

, 2017
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is a chronic eye condition that causes severe deterioration of vision and ultimately blindness. Two vascular endothelial growth factor inhibitors are approved for nAMD treatment in Europe:
Adrian Skelly, Alberto Ferreira, Andriy Danyliv, Julie Glanville, Rachael McCool, Ruth Pulikottil Jacob   +5 more
core   +1 more source

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better

Clinical Ophthalmology, 2019
Arshad M Khanani,1 Greggory M Gahn,2 Micaela M Koci,2 Jonathan M Dang,2 Sandra M Brown,3 Lauren F Hill4 1Sierra Eye Associates, Reno, NV, USA; 2School of Medicine, University of Nevada, Reno, NV, USA; 3Cabarrus Eye Center, Concord, NC, USA; 4Hill  ...
Khanani AM, Gahn GM, Koci MM, Dang JM, Brown SM, Hill LF   +5 more
doaj  

Comparative study on the efficacy of different aflibercept regimens in the treatment of macular edema secondary to branch retinal vein occlusion

Frontiers in Medicine
ObjectivesTo compare the efficacy of intravitreal injection of aflibercept between the treat-and-extend (TAE) and pro re nata (PRN, as needed) regimens in the treatment of macular edema secondary to branch retinal vein occlusion, to determine the best ...
Xing Du, Yuanyuan Guo, Min Du, Wen Wang, Mingkun Liu, Shanshan Li, Yanjuan Sheng   +6 more
doaj   +1 more source

Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration

Türk Oftalmoloji Dergisi, 2019
Objectives:To assess outcomes of a risk-based algorithm-guided treatment protocol for neovascular age-related macular degeneration.Materials and Methods:Two hundred and ten eyes of 184 patients managed with anti-vascular endothelial growth factor (anti ...
Murat Karaçorlu, Mümin Hocaoğlu, Serra Arf, M. Giray Ersöz, Işıl Sayman Muslubaş   +4 more
doaj   +1 more source

Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia

BMC Ophthalmology, 2018
Background To assess visual outcomes over 24 months in patients with neovascular age-related macular degeneration (nAMD) who initiated intravitreal aflibercept therapy under a treat-and-extend (TE) regimen in real-world settings.
Polona Jaki Mekjavić, Bogdan Gregorčič, Cvetka Oberč, Slava Podgoršek   +3 more
doaj   +1 more source

Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol

Medicine, 2017
To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME).Retrospective, single-center study.For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loading phase), after which they were selected for ...
Sugimoto, Masahiko, Ichio, Atsushi, Nunome, Takayasu, Kondo, Mineo   +3 more
openaire   +2 more sources

Efficacy and safety of an aflibercept treat-and-extend regimen in treatment-naïve patients with macular oedema secondary to Central Retinal Vein Occlusion (CRVO) : A Prospective 12-Month, Single-Arm, Multicentre Trial [PDF]

, 2018
To evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO). Design, Setting, and Patients.
Amparo, Navea, Araiz, Javier, Arias Barquet, Lluís, Cervera, Enrique, Crespí, Jaume, De Figueroa, Marta Suárez, Donate, Juan, Fonollosa, Alex, Gallego, Roberto, Garcia Arumi, Jose, Gómez-Ulla, Francisco, Manzanas, Lucia, Universitat Autònoma de Barcelona   +12 more
core   +1 more source

Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration [PDF]

, 2018
The purpose of this chapter is to examine the various treatment strategies used to manage neovascular age-related macular degeneration (nAMD). The chapter will focus on the three main strategies including fixed interval dosing, as needed Pro-Re-Nata (PRN)
Adrean, Sean D., Chaili, Siyang
core   +2 more sources